Online inquiry

IVTScrip™ mRNA-Anti-MAG, GSK-249320(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ7891MR)

This product GTTS-WQ7891MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets MAG gene. The antibody can be applied in Stroke research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001199216.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4099
UniProt ID P20916
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MAG, GSK-249320(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ7891MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14779MR IVTScrip™ mRNA-Anti-CD40, SGN-40(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA SGN-40
GTTS-WQ3445MR IVTScrip™ mRNA-Anti-S, AZD8895(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AZD8895
GTTS-WQ5719MR IVTScrip™ mRNA-Anti-CD3E&CEACAM5, CEA TCB(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CEA TCB
GTTS-WQ2019MR IVTScrip™ mRNA-Anti-INSR, AGT-181(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA AGT-181
GTTS-WQ15262MR IVTScrip™ mRNA-Anti-phosphatidylserine, Tarvacin ch3G4(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA Tarvacin ch3G4
GTTS-WQ10502MR IVTScrip™ mRNA-Anti-APP, LY3002813(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA LY3002813
GTTS-WQ12346MR IVTScrip™ mRNA-Anti-TIGIT, MTIG-7192-A(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MTIG-7192-A
GTTS-WQ14037MR IVTScrip™ mRNA-Anti-LAG3, aLAG367(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA aLAG367
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW